Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.60.

A number of research analysts have issued reports on COLL shares. Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th.

Collegium Pharmaceutical Trading Up 0.8 %

Shares of Collegium Pharmaceutical stock opened at $30.95 on Friday. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a market cap of $998.14 million, a PE ratio of 13.34 and a beta of 0.82. The company has a 50-day moving average of $31.03 and a two-hundred day moving average of $34.14.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of COLL. Victory Capital Management Inc. boosted its position in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after acquiring an additional 215,874 shares during the last quarter. Emerald Advisers LLC boosted its position in Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after acquiring an additional 177,129 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in Collegium Pharmaceutical by 24.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock worth $25,591,000 after acquiring an additional 131,835 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at $4,693,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.